8-K current report · filed Nov 12, 2026

Assembly Biosciences Inc (ASMB) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1ASMB overview

Short answer

Assembly Biosciences Inc (ASMB) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.

Assembly Biosciences Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1, relevant for assessing cash runway and clinical funding ability

Item EX-99.1 · Exhibit EX-99.1

  • Cash, equivalents and marketable securities $314.3M plus $75M Gilead fee, extending projected runway into 2029
  • 40% U.S. HSV program cost and profit share increases future commercial upside and development spending exposure
  • ABI-6250 Phase 2 HDV dosing underway, with cholestatic liver disease Phase 2 targeted for Q1 2027
  • Q3 net loss widened to $20.3M, or $0.93 per share, from $9.2M, or $0.72 per share
  • Collaboration revenue fell to $3.0M from $10.8M, while R&D expense rose to $20.2M from $16.6M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Assembly Biosciences Inc 8-K filings

Get the next ASMB 8-K as it lands

Follow ASMB for push alerts, or ask the research agent what this filing means.